NeoGenomics (NEO) said Wednesday it expects 2025 total revenues in the range of $735 million to $745 million.
Analysts surveyed by FactSet expect $727.8 million.
NeoGenomics said, as part of its long-range financial plan, it intends to achieve 12-13% revenue growth annually and positive cash flow from operations in 2025 and beyond. The company also aims to serve over 1 million patients per year by 2028.
NeoGenomics shares were up almost 4% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.